减瘤性肾切除术在转移性肾细胞癌治疗中的研究进展

doi:10.3969/j.issn.1006-5725.2025.13.002

Abstract

Abstract:

The treatment landscape for metastatic renal cell carcinoma （mRCC） has evolved rapidly over the past two decades with the introduction of targeted therapies and novel immune checkpoint inhibitors. Among these developments， cytoreductive nephrectomy （CN） remains a controversial and unresolved issue， with its survival benefits being questioned compared to systemic therapy （ST）. The role and optimal timing of CN in the context of modern systemic treatment for mRCC remain unclear. Additionally， there is still no well-defined consensus on patient selection for CN. Therefore， this article provides a concise review of current evidence regarding CN in mRCC， incorporating the latest renal cancer management guidelines. We focus particularly on optimal surgical timing， candidate patient selection， and the therapeutic value of metastasectomy. Furthermore， we examine the current role of CN in metastatic non-clear cell renal cell carcinoma and explore its evolving clinical applications and future prospects in mRCC treatment.

Key words: metastatic renal cell carcinoma, cytoreductive nephrectomy, targeted therapy, immunotherapy, metastasectomy

CLC Number:

R737.11

Caifang GUO,Hong FAN,Ting LUAN,Hui ZHAN,Haifeng WANG,Jiansong WANG. The role and research progress of cytoreductive nephrectomy in metastatic renal cell carcinoma[J]. The Journal of Practical Medicine, 2025, 41(13): 1952-1957.

References 47

[1]	SIEGEL R L， MILLER K D， FUCHS H E， et al. Cancer statistics， 2022 ［J］. CA Cancer J Clin， 2022， 72（1）： 7-33. doi:10.3322/caac.21708 doi: 10.3322/caac.21708
[2]	ROSE T L， KIM W Y. Renal Cell Carcinoma： A Review ［J］. JAMA， 2024， 332（12）： 1001-1010. doi:10.1001/jama.2024.12848 doi: 10.1001/jama.2024.12848
[3]	陈锐，熊壮，陈仁富. 白细胞介素38在肾细胞癌中的表达水平及其与临床病理特征的关系［J］. 实用医学杂志， 2022， 38（12）： 1506-1511.
[4]	HUANG J， LEUNG D K， CHAN E O， et al. A Global Trend Analysis of Kidney Cancer Incidence and Mortality and Their Associations with Smoking， Alcohol Consumption， and Metabolic Syndrome ［J］. Eur Urol Focus， 2022， 8（1）： 200-209. doi:10.1016/j.euf.2020.12.020 doi: 10.1016/j.euf.2020.12.020
[5]	BAHADORAM S， DAVOODI M， HASSANZADEH S， et al. Renal cell carcinoma： an overview of the epidemiology， diagnosis， and treatment ［J］. G Ital Nefrol， 2022， 39（3）：2022-vol3.
[6]	BHINDI B， ABEL E J， ALBIGES L， et al. Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond： An Individualized Approach to Metastatic Renal Cell Carcinoma ［J］. Eur Urol， 2019， 75（1）： 111-128. doi:10.1016/j.eururo.2018.09.016 doi: 10.1016/j.eururo.2018.09.016
[7]	ISHIHARA H， TAKAGI T， KONDO T， et al. Prognostic impact of metastasectomy in renal cell carcinoma in the postcytokine therapy era ［J］. Urol Oncol， 2021， 39（1）： 77.e17-77.e25. doi:10.1016/j.urolonc.2020.08.011 doi: 10.1016/j.urolonc.2020.08.011
[8]	DRAGOMIR A， NAZHA S， WOOD L A， et al. Outcomes of complete metastasectomy in metastatic renal cell carcinoma patients： The Canadian Kidney Cancer information system experience ［J］. Urol Oncol， 2020， 38（10）： 799.e791-799.e710. doi:10.1016/j.urolonc.2020.07.021 doi: 10.1016/j.urolonc.2020.07.021
[9]	BRITTON C J， ANDREWS J R， WALLIS C J D， et al. Deferred cytoreductive nephrectomy in the management of metastatic renal cell carcinoma： A systematic review and meta-analysis ［J］. Urol Oncol， 2023， 41（3）： 125-136. doi:10.1016/j.urolonc.2022.09.021 doi: 10.1016/j.urolonc.2022.09.021
[10]	张明津，付伟金. 纳武单抗治疗晚期肾癌的研究进展［J］. 实用医学杂志， 2020， 36（23）： 3184-3188.
[11]	MéJEAN A， RAVAUD A， THEZENAS S， et al. Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma ［J］. N Engl J Med， 2018， 379（5）： 417-427. doi:10.1056/nejmoa1803675 doi: 10.1056/nejmoa1803675
[12]	BEX A， MULDERS P， JEWETT M， et al. Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib： The SURTIME Randomized Clinical Trial ［J］. JAMA Oncol， 2019， 5（2）： 164-170. doi:10.1001/jamaoncol.2018.5543 doi: 10.1001/jamaoncol.2018.5543
[13]	HATAKEYAMA S， NAITO S， NUMAKURA K， et al. Impact of cytoreductive nephrectomy in patients with primary metastatic renal cell carcinoma receiving systemic tyrosine kinase inhibitor therapy： A multicenter retrospective study ［J］. Int J Urol， 2021， 28（4）： 369-375. doi:10.1111/iju.14466 doi: 10.1111/iju.14466
[14]	KATO R， NAITO S， NUMAKURA K， et al. Significance of upfront cytoreductive nephrectomy stratified by IMDC risk for metastatic renal cell carcinoma in targeted therapy era-a multi-institutional retrospective study ［J］. Int J Clin Oncol， 2022， 27（3）： 563-573. doi:10.1007/s10147-021-02091-8 doi: 10.1007/s10147-021-02091-8
[15]	AZAWI N， GEERTSEN L， NADLER N， et al. Cytoreductive Nephrectomy in Select Primary Metastatic Renal Cell Carcinoma Patients： A Comprehensive Nationwide Outcome Analysis ［J］. Cancers （Basel）， 2024， 16（6）：1132. doi:10.3390/cancers16061132 doi: 10.3390/cancers16061132
[16]	PETRELLI F， COINU A， VAVASSORI I， et al. Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma Treated With Targeted Therapies： A Systematic Review With a Meta-Analysis ［J］. Clin Genitourin Cancer， 2016， 14（6）： 465-472. doi:10.1016/j.clgc.2016.04.001 doi: 10.1016/j.clgc.2016.04.001
[17]	CONTI S L， THOMAS I C， HAGEDORN J C， et al. Utilization of cytoreductive nephrectomy and patient survival in the targeted therapy era ［J］. Int J Cancer， 2014， 134（9）： 2245-2252. doi:10.1002/ijc.28553 doi: 10.1002/ijc.28553
[18]	SHAPIRO D D， KARAM J A， ZEMP L， et al. Cytoreductive Nephrectomy Following Immune Checkpoint Inhibitor Therapy Is Safe and Facilitates Treatment-free Intervals ［J］. Eur Urol Open Sci， 2023， 50： 43-46. doi:10.1016/j.eururo.2023.03.042 doi: 10.1016/j.eururo.2023.03.042
[19]	SHIROTAKE S， MIYAMA Y U， BABA Y， et al. Impact of Cytoreductive Nephrectomy Following Nivolumab Plus Ipilimumab Therapy for Patients With Advanced Renal Cell Carcinoma ［J］. Anticancer Res， 2022， 42（5）： 2727-2735. doi:10.21873/anticanres.15751 doi: 10.21873/anticanres.15751
[20]	HARA T， FURUKAWA J， SHIRAISHI Y， et al. Impact of cytoreductive nephrectomy prior to combination therapy of ipilimumab plus nivolumab in metastatic renal cell carcinoma ［J］. Int J Urol， 2023， 30（9）： 746-752. doi:10.1111/iju.15193 doi: 10.1111/iju.15193
[21]	LI K P， CHEN S Y， WANG C Y， et al. The impact of cytoreductive nephrectomy on survival outcomes in patients with metastatic renal cell carcinoma receiving immunotherapy： An evidence-based analysis of comparative outcomes ［J］. Front Immunol， 2023， 14： 1132466. doi:10.3389/fimmu.2023.1132466 doi: 10.3389/fimmu.2023.1132466
[22]	GROSS E E， LI M， YIN M， et al. A multicenter study assessing survival in patients with metastatic renal cell carcinoma receiving immune checkpoint inhibitor therapy with and without cytoreductive nephrectomy ［J］. Urol Oncol， 2023， 41（1）： 51.e25-51.e31. doi:10.1016/j.urolonc.2022.08.013 doi: 10.1016/j.urolonc.2022.08.013
[23]	MITTAL A， AL-EZZI E， LI X， et al. The role of cytoreductive nephrectomy and systemic therapy in the management of tumour thrombus in patients with metastatic renal cell carcinoma ［J］. Br J Cancer， 2023， 128（10）： 1888-1896. doi:10.1038/s41416-023-02166-5 doi: 10.1038/s41416-023-02166-5
[24]	BAKOUNY Z， ZARIF T EL， DUDANI S， et al. Upfront Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors or Targeted Therapy： An Observational Study from the International Metastatic Renal Cell Carcinoma Database Consortium ［J］. Eur Urol， 2023， 83（2）： 145-151. doi:10.1016/j.eururo.2023.03.034 doi: 10.1016/j.eururo.2023.03.034
[25]	MAKRAKIS D， MSAOUEL P， KARAM J A， et al. Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors： A Systematic Review and Meta-analysis of Individual Patient Data ［J］. Eur Urol Focus， 2024：S2405-4569（24）00249-9. doi:10.1016/j.euf.2024.11.007 doi: 10.1016/j.euf.2024.11.007
[26]	SINGLA N， HUTCHINSON R C， GHANDOUR R A， et al. Improved survival after cytoreductive nephrectomy for metastatic renal cell carcinoma in the contemporary immunotherapy era： An analysis of the National Cancer Database ［J］. Urol Oncol， 2020， 38（6）： 604.e609-604.e617. doi:10.1016/j.urolonc.2020.02.029 doi: 10.1016/j.urolonc.2020.02.029
[27]	MORI K， QUHAL F， YANAGISAWA T， et al. The effect of immune checkpoint inhibitor combination therapies in metastatic renal cell carcinoma patients with and without previous cytoreductive nephrectomy： A systematic review and meta-analysis ［J］. Int Immunopharmacol， 2022， 108： 108720. doi:10.1016/j.intimp.2022.108720 doi: 10.1016/j.intimp.2022.108720
[28]	IISAGER L， AHRENFELDT J， DONSKOV F， et al. Multicenter randomized trial of deferred cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma receiving checkpoint inhibitors： the NORDIC-SUN-Trial ［J］. BMC Cancer， 2024， 24（1）： 260. doi:10.1186/s12885-024-11987-3 doi: 10.1186/s12885-024-11987-3
[29]	BELL H， COTTA B H， SALAMI S S， et al. "PROBE"ing the Role of Cytoreductive Nephrectomy in Advanced Renal Cancer ［J］. Kidney Cancer J， 2022， 6（1）： 3-9. doi:10.3233/kca-210010 doi: 10.3233/kca-210010
[30]	DE BRUIJN R， WIMALASINGHAM A， SZABADOS B， et al. Deferred Cytoreductive Nephrectomy Following Presurgical Vascular Endothelial Growth Factor Receptor-targeted Therapy in Patients with Primary Metastatic Clear Cell Renal Cell Carcinoma： A Pooled Analysis of Prospective Trial Data ［J］. Eur Urol Oncol， 2020， 3（2）： 168-173. doi:10.1016/j.euo.2019.12.004 doi: 10.1016/j.euo.2019.12.004
[31]	BHINDI B， GRAHAM J， WELLS J C， et al. Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma ［J］. Eur Urol， 2020， 78（4）： 615-623. doi:10.1016/j.eururo.2020.04.038 doi: 10.1016/j.eururo.2020.04.038
[32]	FONG K Y， LIM E J， WONG H C， et al. Deferred cytoreductive nephrectomy in patients with metastatic renal cell carcinoma： A systematic review and patient-level meta-analysis ［J］. Urol Oncol， 2025，43（6）：348-358. doi:10.1016/j.urolonc.2024.12.272 doi: 10.1016/j.urolonc.2024.12.272
[33]	POWLES T， ALBIGES L， BEX A， et al. Renal cell carcinoma： ESMO Clinical Practice Guideline for diagnosis， treatment and follow-up ［J］. Ann Oncol， 2024， 35（8）： 692-706. doi:10.1016/j.annonc.2024.05.537 doi: 10.1016/j.annonc.2024.05.537
[34]	GHATALIA P， HANDORF E A， GEYNISMAN D M， et al. The Role of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma： A Real-World Multi-Institutional Analysis ［J］. J Urol， 2022， 208（1）： 71-79. doi:10.1097/ju.0000000000002495 doi: 10.1097/ju.0000000000002495
[35]	CHEN B， LI J， HUANG Y， et al. The role of cytoreductive nephrectomy in metastatic renal cell carcinoma in the targeted therapy and immunological therapy era： a systematic review and meta-analysis ［J］. Int J Surg， 2023， 109（4）： 982-994. doi:10.1097/js9.0000000000000314 doi: 10.1097/js9.0000000000000314
[36]	YANG W， MA L， DONG J， et al. Machine learning to improve prognosis prediction of metastatic clear-cell renal cell carcinoma treated with cytoreductive nephrectomy and systemic therapy ［J］. Biomol Biomed， 2023， 23（3）： 471-482.
[37]	ZHANG Y， HU J， YANG J， et al. Selection of Optimal Candidates for Cytoreductive Nephrectomy in Patients with Metastatic Clear Cell Renal Cell Carcinoma： A Predictive Model Based on SEER Database ［J］. Front Oncol， 2022， 12： 814512. doi:10.3389/fonc.2022.814512 doi: 10.3389/fonc.2022.814512
[38]	LYON T D， THOMPSON R H， SHAH P H， et al. Complete Surgical Metastasectomy of Renal Cell Carcinoma in the Post-Cytokine Era ［J］. J Urol， 2020， 203（2）： 275-282. doi:10.1097/ju.0000000000000488 doi: 10.1097/ju.0000000000000488
[39]	MEYER C P， GROEBEN C， MARKS P， et al. Trends of Metastasis-Directed Treatments in Patients with Renal Cell Carcinoma： A Total Population-Based Analysis in Germany in the Era of Targeted Therapies ［J］. Oncol Res Treat， 2020， 43（12）： 679-685. doi:10.1159/000511753 doi: 10.1159/000511753
[40]	SUN M， MEYER C P， KARAM J A， et al. Predictors， utilization patterns， and overall survival of patients undergoing metastasectomy for metastatic renal cell carcinoma in the era of targeted therapy ［J］. Eur J Surg Oncol， 2018， 44（9）： 1439-1445. doi:10.1016/j.ejso.2018.05.026 doi: 10.1016/j.ejso.2018.05.026
[41]	WU K， LIU Z， SHAO Y， et al. Nomogram Predicting Survival to Assist Decision-Making of Metastasectomy in Patients With Metastatic Renal Cell Carcinoma ［J］. Front Oncol， 2020， 10： 592243. doi:10.3389/fonc.2020.592243 doi: 10.3389/fonc.2020.592243
[42]	NAIK P， DUDIPALA H， CHEN Y W， et al. The incidence， pathogenesis， and management of non-clear cell renal cell carcinoma ［J］. Ther Adv Urol， 2024， 16： 17562872241232578. doi:10.1177/17562872241232578 doi: 10.1177/17562872241232578
[43]	WILSON N R， ACIKGOZ Y， HASANOV E. Advances in non-clear cell renal cell carcinoma management： From heterogeneous biology to treatment options ［J］. Int J Cancer， 2024， 154（6）： 947-961. doi:10.1002/ijc.34756 doi: 10.1002/ijc.34756
[44]	GRAHAM J， WELLS J C， DONSKOV F， et al. Cytoreductive Nephrectomy in Metastatic Papillary Renal Cell Carcinoma： Results from the International Metastatic Renal Cell Carcinoma Database Consortium ［J］. Eur Urol Oncol， 2019， 2（6）： 643-648. doi:10.1016/j.euo.2019.03.007 doi: 10.1016/j.euo.2019.03.007
[45]	程军，骆文龙. 尿微量白蛋白检测对妊娠期高血压患者早期肾损伤的诊断价值分析［J］. 药物生物技术，2024，31（1）：67-70.
[46]	MARCHIONI M， BANDINI M， PREISSER F， et al. Survival after Cytoreductive Nephrectomy in Metastatic Non-clear Cell Renal Cell Carcinoma Patients： A Population-based Study ［J］. Eur Urol Focus， 2019， 5（3）： 488-496. doi:10.1016/j.euf.2017.11.012 doi: 10.1016/j.euf.2017.11.012
[47]	MOTZER R J， JONASCH E， AGARWAL N， et al. NCCN Guidelines® Insights： Kidney Cancer， Version 2.2024 ［J］. J Natl Compr Canc Netw， 2024， 22（1）： 4-16.

The role and research progress of cytoreductive nephrectomy in metastatic renal cell carcinoma

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 47

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Kui XU,Jun. ZHOU. Research progress of ultrasound microbubbles in diagnosis and treatment of thyroid cancer [J]. The Journal of Practical Medicine, 2025, 41(3): 454-458.
[2]	Qiang FU,Zhongqi LU,Ying CHANG,Tiefeng JIN,Meihua. ZHANG. Research progress on the antitumor effects of immune checkpoint inhibitors [J]. The Journal of Practical Medicine, 2025, 41(2): 288-293.
[3]	Xingyu WAN,Nan LI,Shuiqing LIU,Xi. ZHANG. Research advances of mesenchymal stem cells in the bone marrow microenvironment of acute myeloid leukemia [J]. The Journal of Practical Medicine, 2025, 41(2): 294-299.
[4]	Zegong HU,Yan BAI. Research advances in allergen-specific immunotherapy [J]. The Journal of Practical Medicine, 2025, 41(11): 1760-1766.
[5]	Fazhu FEI,Jiajun LU,Shuai ZHANG,Hao LI,Bin REN. Clinical application progress of immunization and targeted therapy for Hepatocellular Carcinoma in special populations [J]. The Journal of Practical Medicine, 2024, 40(6): 738-742.
[6]	Jiang SHAO,Lin LI,Yansong GUO,Chengyuan SUN,Xichao WEN,Kebin ZHENG,Yanfang SHI. Research progress of CD73/NT5E in glioblastoma [J]. The Journal of Practical Medicine, 2024, 40(3): 428-431.
[7]	Zhaochen SUN,Junyan JIANG,Yitian. CHEN. Advancements in CAR⁃T cell research for the treatment of colorectal cancer [J]. The Journal of Practical Medicine, 2024, 40(18): 2640-2646.
[8]	Sishi XU,Peipei. YE. Clinical research progress of BTK inhibitors in the treatment of mantle cell lymphoma [J]. The Journal of Practical Medicine, 2024, 40(17): 2363-2368.
[9]	Yuting LI,Qilu YAN,Qibin. SONG. Molecular basis of variability in EGFR⁃targeted therapy response in non⁃small cell lung cancer [J]. The Journal of Practical Medicine, 2024, 40(15): 2166-2171.
[10]	Ziqi DING,Qian. ZHANG. Research progress in T cell exhaustion and its relationship with respiratory diseases [J]. The Journal of Practical Medicine, 2024, 40(13): 1895-1900.
[11]	Jingwen AN,Junyun FENG,Lei RAO,Dewu LIU. Research progress on relationship between cellular senescence and scar fibrosis [J]. The Journal of Practical Medicine, 2024, 40(12): 1749-1754.
[12]	Yawei ZHANG,Hongjin SHI,Shi FU,Jiansong WANG,Haifeng WANG. Research progress in biological role of TIGIT and its application in bladder cancer [J]. The Journal of Practical Medicine, 2024, 40(12): 1762-1766.
[13]	Xizhi WEN,Xiaoshi. ZHANG. Immunotherapy based on neoantigen： A personalized treatment strategy for melanoma [J]. The Journal of Practical Medicine, 2024, 40(10): 1331-1337.
[14]	WU Kaiyi, LÜ Xuedong, HE Haiyan, CHEN Jinliang. . Progress in the application of cryoablation combined with immunotherapy in the treatment of NSCLC [J]. The Journal of Practical Medicine, 2023, 39(8): 1058-1062.
[15]	ZHANG Xijie, LI Xin, ZHOU Wence.. Research progress of combined immunotherapy for metastatic pancreas cancer [J]. The Journal of Practical Medicine, 2023, 39(6): 655-659.